Extending A Patent's Term to Protect Your Market Share
This article was originally published in The Gray Sheet
Patent attorneys Kirsten Johnson and Les Bookoff detail the patent term extension process, which, they say, is a crucial tool for device companies to maximize return on investments for innovative new technologies.
You may also be interested in...
A settlement between the two companies dismissing all pending patent litigation related to transcatheter valve replacement technologies ends years of legal wrangling and ensures that the U.S. TAVR market will have at least two competitors.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.